Despite the proven tumorigenic role of SLC3A2 in a number of cancers including head and neck squamous cell carcinomas (HNSCC), it is also a novel therapeutic approach for advanced prostate cancer [51]. The gene discussed is SLC3A2; the disease is prostate carcinoma.